Kyn Therapeutics Merck ARY-007

Kyn Therapeutics and Merck begin Phase Ib/I trials of ARY-007

Kyn Therapeutics in collaboration with Merck has commenced two clinical trials of EP4 receptor antagonist ARY-007. ARY-007 (grapiprant) is an oral, potent…